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We aimed to characterize specific MRI findings seen in immune competent patients with intracranial primary CNS
lymphoma (PCNSL) and to determine their value in the management of such patients. Pre-treatment MRI
examinations of 21 immunocompetent patients with biopsy-proven PCNSL were retrospectively evaluated. T1 and
T2 signal characteristics as well as contrast enhancement features are described in all patients. Diffusion, perfusion
and proton-MR-spectroscopy features are described in a subset of these patients. In the proper clinical and
radiologic setting, suggesting the diagnosis of PCNSL can help institute proper treatment in a timely fashion and
avoid unnecessary attempts at surgical resection and the associated morbidity.
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Involvement of the central nervous system by lymph-
oma can occur in the presence of systemic lymphoma
involvement (secondary) or in isolation as a primary
CNS neoplasm.
Primary central nervous system lymphoma (PCNSL),
the focus of this article, originates in the brain, leptomen-
inges, spinal cord, or eyes and typically remains confined
to the CNS; with only rare spread outside the nervous
system. It was initially described by Bailey as perivascular
sarcoma [1] and is a rare tumor accounting for 2-6% of
all primary brain tumors and 1-2% of all non-Hodgkin
lymphomas [2].
PCNSL in the vast majority of patients is a subtype of
non-Hodgkin’s lymphoma (NHL), and is usually large cell
or immunoblastic type, and is by definition restricted to
the CNS (stage IE) [1,3].
PCNSL is encountered in the immunocompetent and
in the immunocompromised patients, but the cause and
behavior of PCNSL differ based on the affected population.
Immunocompromised patients are at particular risk for
developing PCNSL which is typically secondary to HIV,
organ transplantation, or congenital immunodeficiency* Correspondence: habuali@khcc.jo
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unless otherwise stated.syndromes. In this setting, PCNSL arises from Epstein-
Barr virus (EBV) infection of B-lymphocytes. In contrast,
there is no well-established cause for PCNSL in immuno-
competent patient. No correlation has been found between
the disease and EBV or the human herpes viruses in this
immune competent population [3]. Additionally, it has
been and still is a mystery, how these neoplasms develop
and grow in the CNS given that B-lymphocytes have no
known role in normal brain [3].
There are no pathognomonic imaging features for
PCNSL. However, the clinical presentation and imaging
features can be quite specific (Table 1). Although brain
biopsy remains the gold standard for diagnosis, surgical
resection does not improve outcome and chemotherapy
remains the mainstay for treatment. Therefore, early
diagnosis of CNS lymphoma is crucial for proper man-
agement and it is more likely if the correct diagnosis
was suggested initially.
PCNSL typically involves the supratentorial brain and
the lesions are most typically in contact with ventricular
or meningeal surfaces. The lesions can also be deeply
seated in the parenchyma. The most commonly involved
sites include periventricular white-matter, deep gray nuclei,
corpus callosum and superficially adjacent to CSF spaces
[3]. Atypical locations include brainstem, cranial nerves,
cavernous sinuses, pineal gland and pituitary gland.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary for all MRI findings in 21 patients with primary CNS lymphoma
Patient Age Sex Location (number of lesions) T1WI T2WI DWI Enhancement Multiplicity Calcifications Hemorrhage Edema Meningeal
enhancement
1 42 y M Suprasellar (1) Iso Hypo Restricted +++ Single - - +++ -
2 32 y M HWM (1) Iso Iso Restricted +++ Single - - +++ -
3 55 y M HWM (1) Hyper Iso Restricted +++ Single - + - -
4 46 y F Cerebellum (1) Hypo Iso Restricted +++ Single - - ++ -
5 65 y M HWM (1) Hypo Iso Restricted +++ Single - - ++ -
6 62 y F HWM (2) Hypo Hyper Restricted +++ 2 lesions - - ++ -
7 68 y F HWM (1) Iso Hypo Restricted +++ Single - - +++ -
8 50 y M Subependyma (2), Basal ganglia
(1) and Brainstem (1)
Iso Iso N\A +++ 4 lesions - - +++ -
9 28 y M Basal ganglia (1) Iso Iso Restricted + Single - - +++ -
10 39 y M HMW (1), Suprasellar (1),
Basal ganglia (1)
Iso Hyper Restricted +++ 3 lesions - - ++ +
11 19 y M Cerebellum (2) and HWM (2) Iso Iso Iso +++ 4 lesions - - +++ -
12 45 y M Fourth (1) and lateral ventricle (1) Hyper/Iso* Iso Iso +++ 2 lesions - +/-* - -
13 37 y M HWM (2) Hypo Hyper N\A ++ 2 lesions - - + -
14 65 y M HWM (3) Hypo Iso Restricted +++ 3 lesions - - +++ +
15 28 D M Corpus callosum (Splenium) (1) Iso Iso N\A +++ Single - - +++ -
16 70 y F HWM (1) Iso Iso Restricted +++ Single - - ++ -
17 38 y F Basal ganglia (1), Subependyma (1), Iso Iso Restricted +++ 3 lesions - - ++ -
Brain stem (1)
18 67 y F HWM (1) Iso Iso Restricted +++ Single - - ++ -
19 71 y M Corpus callosum (Splenium) (1) Iso Iso Iso + Single - - - -
20 37 y F HWM (1) Hypo Iso Restricted + Single - - ++ -
21 47 y M Suprasellar (1) Iso Hypo Iso ++ Single - - - -
HWM: Hemispheric white matter.
N/A: Not available.
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are quite rare. This fact contributes to the relatively homo-
geneous appearance of PCNSL on imaging. When present,
hemorrhage and calcification can alter the signal intensity,
depending on the age of the hemorrhage and the compos-
ition of the calcification [4].
PCNSL usually appears hyperdense on non-contrast
enhanced CT scan which reflects hypercellularity of the
tumor and the high nuclear/cytoplasmic ratio. This gives
on MR imaging the classical iso-to-hypointense signal
(relative to grey-matter) on both T1- and T2-weighted
images [4-6]. Following intravenous contrast injection,
PCNSL tends to show moderate-to-intense enhancement
in the majority of cases which implies disruption of the
blood–brain barrier. In contrary to the most common pri-
mary brain tumor (glioblastoma multiforme), gross necrosis
is absent in these tumors. Perilesional edema/signal abnor-
mality is a common feature of PCNSL. It is present in more
than 90% of lesions. The edema is mostly moderate-to-
severe (larger than the enhancing area) [2].
In this article, we review the specific MR imaging fea-
tures of PCNSL in immunocompetent individuals which
can help radiologists reach the correct diagnosis and
start treatment without delay or unnecessary surgical
intervention.
Case presentation
Most of our patients complained from non specific symp-
toms like headache, seizure and change in mental status.
On the other hand, few of them complained from focal
neurological deficient typical of a mass effect. Cranial
nerve symptoms and vertigo were also noticed in few pa-
tients. The systemic symptoms like fever, night sweet and
weight loss were very rare.
Patients and methods
We reviewed the clinical data and imaging features at
presentation of 14 male and 7 female immune compe-
tent patients with ages ranging from 28 years to 71 years
who were diagnosed histopathologically with intracranial
PCNSL over a period of 8 years (from January 2004 to
August 2012) in King Hussein Cancer Center, Amman,
Jordan.
Two experienced radiologists independently reviewed
and analyzed the images retrospectively. All scans were
reviewed noting lesion location in the brain, size, margin,
and the signal characteristics. The presence of calcifica-
tions, hemorrhage, perilesional edema, meningeal enhance-
ment and the characteristics of enhancement were also
examined. Disagreements were resolved with consensus.
All patients had FLAIR, T2- and T1-weighted images.
Post-contrast T1-weighted images were also obtained
in all patients. Diffusion-weighted MRI (DW-MRI) was
available in 18 patients, while proton-MR-spectroscopy(1H-MRS) was available in 6 patients. Perfusion MR im-
aging was performed also in 6 patients. Most of the
studies were obtained on a 1.5 Tesla Siemens Magne-
tom Avanto machine. On this machine, the acquired T1
and T2 images were fast spin-echo sequences with TR
500 ms and TE 7.8 ms for T1 and TR 3630 ms and TE
93 ms for T2. For FLAIR, TR 8700 ms and TE 84 ms
values were used. Slice thickness was 6 mm for all se-
quences. T1 sequences were obtained along the three
orthogonal planes pre- and post-contrast. The T2 and
FLAIR sequences were obtained axially. The DWI was
obtained using B-values of 0, 500 and 1000 s/mm2. Two
of the later cases were imaged on a 3 Tesla Philips Inge-
nia machine. The pre- and post-contrast T1 sequences
were isotropic, ultrafast spoiled gradient echo sequences
(TR 8.3 ms and TE 3.8 ms). For T2, a 5 mm axial fast
spin echo sequence with TR 4000 ms and TE 110 ms
was obtained. For FLAIR, the TR and TE values were
11000 ms and 125 ms, respectively. MR spectroscopy
was performed with a long echo time (135 ms) as a mul-
tivoxel 2D exam encompassing the lesion and normal-
appearing white-matter.
The contrast used in all these MR exams was Opti-
Mark™ (0.5 mmol/ml gadoversetamide injection from
Mallinckrodt Inc.) which was administered intraven-
ously at a dose of 0.2 mL per kg body weight.
T1, T2 and FLAIR sequences were examined qualita-
tively. Both the DWI images and the ADC maps were
examined qualitatively and quantitatively. The mean ADC
values in the lesions and in the contralateral normal-
appearing white-matter were measured and a ratio was
calculated. The MR perfusion maps were also studied in
the same way, qualitatively and quantitatively. The cere-
bral blood volume (CBV) values were determined in the
lesions and in the contralateral normal-appearing white-
matter and the ratio (rCBV) was calculated. For proton
MR Spectroscopy, the ratios of the major metabolites
(Choline, N-acetylaspartate and Creatine) were deter-
mined. Also, the presence of lipid peaks was determined.
The exams were reviewed on Brilliance Workspace Portal
(by Philips). The diffusion and perfusion values were ob-
tained on Syngo Via workstation (by Siemens).
Results
The 21 patients exhibited 36 lesions. Fourteen of twenty
one patients (66.7%) were males. Thirteen patients have
a solitary lesion (62%) and the other eight patients have
multiple lesions (two lesions seen in three patients, three
lesions seen in three patients and four lesions seen in
two patients).
Most of the lesions (30 lesions) were located supratento-
rially (83.3%) and the most common site supratentorially
was the hemispheric white-matter (17 lesions (56.7%)).
Representative T2WI, precontrast T1WI and postcontrast
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through 1d. Four lesions were seen in the basal ganglia, 3
lesions in suprasellar region (Figure 2a through 2c), 3 le-
sions were subependymal, 2 lesions were found in corpus
callosum and 1 was in the lateral ventricle. Only 6 lesions
were in the infratentorium, three of them in the cerebel-
lum, two in the brainstem and one in the fourth ventricle.
On T1 sequences, 24 lesions (66.7%) were isointense, 10
lesions (27.8%) were hypointense and only 2 lesions (5.5%)
were hyperintense relative to gray-matter (Figure 3). On
the other hand, 26 lesions (72.2%) were isointense, 3 le-
sions were hypointense and 7 lesions (19.5%) were hyper-
intense on T2 sequences relative to gray-matter.
Perilesional edema or signal abnormality was present
in 31 lesions ranging from mild in two lesions, moderate
in thirteen lesions and marked in 16 lesions. The degree
of edema was judged and reported as follows: a mean
diameter of peritumoral edema of less than 10 mm was
graded as mild, a mean diameter of 11–20 mm of peritu-
moral edema was graded as moderate, while marked was
used when the mean diameter of peritumoral edema was
more than 20 mm. The degree of mass-effect was judged
subjectively depending on the degree of displacement
and/or compression of the adjacent structures.
The degree of enhancement was variable. Most of the
lesions (30 lesions out of 36) were intensely enhancing
(83.3%), three lesions showed minimal enhancement and
the remaining three lesions showed moderate enhancement.Figure 1 Axial T2WI, T1WI and contrast-enhanced T1WI as well as AD
the mass is isointense to mildly hypointense on T2WI and isointense
intense contrast enhancement (1a-1d). The mass is also in a typical distr
callosum abutting the lateral ventricles in this case). The mass is associated
the mass shows diffusion restriction.All lesions were diffusely and homogeneously contrast-
enhancing (no necrosis). None of the lesions showed no
enhancement. However, some of the lesions showed a
slit-like center (Figure 4).
Only two lesions out of 36 showed hemorrhagic changes
(6%) and two out of 21 patients showed meningeal en-
hancement (10%). None of the lesions showed calcification.
Diffusion-weighted MRI (b = 1000 s/mm2) was available
in 18 patients. By visual inspection, areas of restricted dif-
fusion were present in 72.4% (n = 21/29) of the lesions in
the form of increased signal on DWI and iso to low signal
on ADCmaps relative to cerebral white-matter (Figure 1d).
Mean ADClym/ADCwm for all lesions measured (including
the non-diffusion-restricted ones) was 1.4. The ADC ratio
range was between 0.91 and 3.00.
MR spectroscopy showed marked increase in choline
(Cho) and marked reduction in N-acetylaspartate (NAA)
peaks (Figure 5). The average Cho/Cr ratio was 3.14
(with a range of 1.67 - 5.82). The average Cho/NAA ratio
is 1.2 (with a range of 0.94 – 1.76). There is also a large
lipid peak in all cases. This spectroscopic finding was ob-
served in the enhancing component as well as the area ad-
jacent to it (transitional area).
Perfusion-weighted MR imaging was performed in 6
patients (total of 8 lesions). PWI shows marked reduction
in rCBV (relative to the contralateral normal-appearing
white-matter) in 5 lesions (Figure 6a and 6b). The average
rCBV was 0.67 (range of 0.03 -2.0).C and DWI maps show the classic appearance of PCNSL where
on T1WI (relative to gray-matter) and shows predominantly solid,
ibution abutting a CSF-containing space (in the splenium of the corpus
with extensive perilesional T2-hyperintensity. On ADC and DWI,
Figure 4 Axial post-contrast T1WI shows a slit-like center (white
arrow) in an otherwise intensely, solidly contrast-enhancing
mass in the right frontal white-matter. The mass causes little
mass-effect relative to its large size.
Figure 3 Axial pre-contrast T1WI shows a hyperintense mass in
the right temporal lobe.
Figure 2 Post-contrast T1WI in the axial, coronal and sagittal
planes show two intensely, solidly contrast-enhancing masses
(2a-2c). The larger one involves the hypothalamus and optic chiasm
as well as the pituitary gland. The other one is subcortically located
in the left temporal lobe.
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One of the major issues physicians face while dealing
with PCNSL diagnosis, is that it is not a frequent possi-
bility in CNS pathology. In one study by Haldorsen et al.
[2], the median time from imaging to diagnosis in non-
AIDS PCNSL differed according to the pattern of imaging
abnormalities (was 32, 3, 5, and 3 weeks for patients with
no, single, multiple, or disseminated lesions, respectively).
Patients with no or disseminated lesions were more often
diagnosed at postmortem examination [2]. This delay in
diagnosis and treatment can negatively impact outcome
and prognosis [7].
Although PCNSL has no pathognomonic imaging fea-
tures, it often has a characteristic appearance on both
Figure 5 Spectroscopy at echo time of 135 msec shows
elevation of choline (Cho) and marked reduction of
N-acetylaspartate (NAA). In addition, there is a large lipid peak
(white arrow).
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cluding its hypercellularity, high nuclear/cytoplasmic ratio,
disruption of the blood–brain barrier, and its predilection
for the periventricular and superficial regions, often in
contact with ventricular or meningeal surfaces [4]. Despite
these characteristic imaging features, none of these canFigure 6 Axial post-contrast T1WI and cerebral blood volume color m
volume values in the tumor (6a-b).unequivocally differentiate CNS lymphoma from other
brain lesions [4].
Early diagnosis of PCNSL is especially important given
that the treatment of PCNSL differs substantially from
other CNS tumors. A visible tumor on imaging is essen-
tial to raise the suspicion of CNS lymphoma in the first
place. This then can lead to an early histological diagnosis.
For this reason steroids should be avoided in suspected
PCNSL, with the exception of patients who show evidence
of impending brain herniation. A minimally invasive and
accurate diagnosis of PCNSL is therefore an important
goal that could clearly alter patient treatment and reduce
the risk of complication. The preferred method of diagno-
sis of PCNSL is imaging-guided stereotactic biopsy and
CSF cytology [2].
PCNSL is very chemo- and radiosensitive and early
diagnosis can significantly affect outcome. Therapeutic
advances due to systemic chemotherapy with or without
radiation therapy have been reported with median sur-
vival times of 33–60 months. Young age and good per-
formance status are favorable prognostic factors [2].
Rarely, PCNSL manifests in a totally different pattern
where the brain is diffusely involved. It is called then lym-
phomatosis cerebri. This distinct entity is typically charac-
terized by diffuse leukoencephalopathy without contrast
enhancement, and is considered a diagnostic challenge [8].
Traditional imaging findings
PCNSL typically presents as a solitary parenchymal mass.
Multiple lesions have been reported in 20-40% of non-
AIDS PCNSLs. This is in contrast to secondary involve-
ment of the CNS by lymphoma which tends to presentap from perfusion exam show the reduced cerebral blood
Figure 7 Axial post-contrast T1WI shows a subcortical lesion
with two deep indentations reflecting the overlying sulci (two
overlapping crescents).
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chymal disease in only one-third of cases [4].
PCNSL typically involves the supratentorial brain and
typically the lesions are in contact with ventricular or
meningeal surfaces. We observed a similar distribution
of the lesions in our population. We also observed few
lesions in atypical locations like the brainstem, and cere-
bellum. Few were suprasellar and intraventricular as well.
Hemorrhage or internal calcification within the tumor are
atypical features and are quite rare [9]. We observed
hemorrhage in only 2 of the 36 lesions which accounted
for the two lesions that exhibited T1-hyperintensity in our
study. We observed no calcification in any of the lesions.
The lack of such atypical imaging features among our pa-
tients probably reflects the fact that our patients were all
immunocompetent and have not been treated with radi-
ation or antineoplastic agents prior to imaging [10].
PCNSL often has a characteristic appearance on both
CT and MR imaging reflecting its hypercellularity and
the high nuclear/cytoplasmic ratio. In our patients, we
observed isointensity to gray-matter on both T1 and T2
sequences in the majority of lesions (about 70%).
We observed contrast enhancement in all our lesions.
It was intense in 30 of the 36 lesions. The contrast en-
hancement was diffuse and homogeneous in all cases
(no ring-like enhancement or necrosis). This is compatible
with what has been reported [4]. In the literature, ring-like
enhancement was the most common pattern in PCNSL in
AIDS patients [4]. Also and in contrary to the most com-
mon primary brain tumor (glioblastoma), gross necrosis
was absent in our population. Lymphoma has been de-
scribed to uncommonly present as a non-enhancing white-
matter hyperintensity on T2WI (lymphomatosis cerebri).
We did not encounter any similar case in our study.
We also noticed that when the PCNSL lesion occurs
in subcortical location, it respects the cortex and its
morphology (the lesion wraps around the cortex giving
the appearance of a crescent) (Figure 7). We observed this
in most of the cases located in the subcortical white-
matter and it probably reflects the soft, infiltrative nature
of these tumors. As far as we know, this is the first de-
scription of this feature in association with PCNSL The
lesions in our population also did not seem to cause
proportionate mass-effect (relative to their size) which
can be similarly explained by the soft, infiltrative nature
of the disease.
We didn’t encounter any cysts (tumoral or reactive) in
our patients. A recent article about brain tumors mani-
festing as cyst with a mural nodule did cite only one case
of PCNSL in which the cysts was related to an adjacent
synchronous epidermoid cyst [11,12].
Leptomeningeal enhancement was present in 2 of our 21
patients. The rate of such involvement in our population is
slightly higher than what has been reported (1%) [13].Edema is a common feature of PCNSL. Some published
data reports the edema in 77% of the lesions, though
usually less prominent than that in malignant gliomas or
metastases [4]. We observed edema in 90 of the lesions
in our population. The edema was mostly moderate-to-
severe, though, as described above, the mass-effect is
less than what is expected for the same mass size.Diffusion weighted imaging
DWI measures the diffusion of water molecules in bio-
logic tissues. It is a surrogate marker of tumor cellular-
ity. Highly cellular tumors, like CNS lymphoma, would
demonstrate a relative decrease in apparent diffusion co-
efficient (ADC) values [14].
We observed subjective diffusion restriction (hyperinten-
sity on DWI and iso- to hypointensity on ADC maps) in
21 of 29 lesions. Mean normalized ADC values (ADClym/
ADCwm) for all lesions measured (including the non-
diffusion-restricted ones) was 1.4. The ADC ratio range
was between 0.91 and 3.00.
These values are slightly higher than what has been
described in literature but remain an important clue in
differentiating high-grade astrocytoma from lymphomas.
In one study, the mean ADC ratio of lymphomas was
1.15 and that of high-grade astrocytomas was 1.68 [15].
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with nuclear-to-cytoplasmic (N/C) ratio on histology.
In addition, pretherapeutic ADC tumor measurement
within the contrast-enhancing part of the tumor has been
shown to be predictive of the clinical outcome (lower
ADC meant shorter progression-free survival and overall
survival) [16]. It also can be used as a biomarker to moni-
tor response to treatment, where increasing ADC values
suggest favorable response [4].
Perfusion-weighted MR imaging (MRP)
While contrast enhancement reflects leakiness of the ves-
sels (disruption of the blood–brain barrier), perfusion as-
sesses tumor vascularity. The documented importance of
revascularization through angiogenesis for tumor growth
has led to a growing interest in such imaging techniques.
Perfusion MR and CT imaging visualize nutritive delivery
of arterial blood to the capillary bed in the biologic tissue
(e.g., tumors). Postprocessing of the acquired data allows
for calculation of physiologic parameters, such as cerebral
blood volume, cerebral blood flow, mean transit time, and
time to peak [4].
In our patient cohort, the average rCBV was 0.84 with
a range from 0.23 to 1.9. It was calculated as a ratio of
the signal in the lesion relative to the contralateral, nor-
mal–appearing white-matter. This is consistent with
what has been described in the literature. The low rCBV
in lymphoma might be attributed to the characteristic
angiocentric growth pattern. This perivascular infiltration
also leads to massive leakage of contrast media in the
interstitial space which accounts for a characteristic inten-
sity time curve. This low CBV coupled with the character-
istic intensity time curve may play an important role in
differentiating PCNSL from the other frequently encoun-
tered differential diagnosis including glioblastoma multi-
forme and metastases both of which show significantly
higher rCBV values [4].
MR spectroscopy (MRS)
MRS allows for noninvasive acquisition of biochemical in-
formation from biologic tissues. Within a defined volume
of interest, signals are registered from chemical nuclei; the
most commonly used nuclei are protons (hydrogen).
In our PCNSL patients, MRS (at TE 135 ms) consist-
ently showed increased choline and decreased NAA along
with the presence of lipid peak. This is consistent with
what has been described in literature [17-19] and while
it may not help differentiate PCNSL from glioblastoma
multiforme and metastases (which can show similar
findings), it may help in differentiating PCNSL from
other lesions [4].
We also noticed a transition zone of abnormal spectra
outside the enhancing area reflecting the infiltrative
pattern of lymphoma which extends beyond the contrast-enhancing region. This might aid in differentiating PCNSL
from metastasis but not from high grade glioma.Conclusion
PCNSL is a highly malignant tumor which requires dif-
ferent approach in diagnosis and management compared
to other high-grade malignant brain tumors. Suggesting
the correct diagnosis prior to steroid administration or
unnecessary surgical procedures is frequently achievable
based on characteristic imaging features. PCNSL typic-
ally present as a homogenous mass with T1 and T2
signal intensity that reflects high-cellularity characteris-
tics. The mass typically shows diffuse, homogeneous
contrast-enhancement. The lesions typically have less
mass-effect than a comparable size metastasis or high-
grade glioma. In a subcortical location, the mass may re-
spect the overlying cortex resulting in a crescent-shaped
morphology. Necrosis, hemorrhage and calcifications are
atypical features and are rare in these tumors.
New imaging techniques (MRS, PWI and DWI) play
important role in the diagnosis of PCNSL and differenti-
ating it from other primary and secondary brain tumors
(high-grade gliomas and metastases). This is especially
important when the characteristic imaging features on
traditional imaging are absent.
Comparing what we have found in our population and
what has been described in the literature for PCNSL and
other brain tumors, we find that PWI can be very help-
ful in differentiating PCNSL from other high-grade brain
tumors which is consistent with the results from other
studies. In addition, rCBV ratio is significantly lower in
PCNSL compared to what has been described for high-
grade glial brain tumors and metastasis. ADC on DWI is
also lower in PCNSL compared to the high-grade glial tu-
mors and metastasis, but may not be as accurate as the
rCBV in differentiating PCNSL from high-grade glioma
(glioblastoma multiforme and anaplastic astrocytoma) and
metastases. The lipid peak on MR spectroscopy seems to
be a consistent finding as well.Consent
Written informed consent was obtained from each pa-
tient for the publication of this report and any accom-
panying images.
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